In the Research Briefing of June 24th 1) Are patients ready for psychedelics as medicines? A survey study provides answers 2) Microdosing for creativity still not catching a break 3) Ketamine helps those with chronic migraines find temporary relief
In the Research Briefing of June 10th 1) Using machine learning to predict who will quit alcohol and opioids after a psychedelic trip 2) Positive outcomes after an ayahuasca retreat, with improvements at the 6-month follow-up 3) The fMRI data for psychedelic neuroimaging is less organized than one hopes for
In the Research Briefing of June 3rd 1) Reducing negativity bias in depressed patients with psychedelics 2) Psychedelic trials focus mainly on MDMA and psilocybin at this time 3) Positive long-term outcomes after bad trips and a more complete picture of such experiences
This is all the other psychedelic research that came out in June 2021.
Psychedelic research in May saw the MAPS MDMA study data, psychedelics and genes, and many psychedelic center studies.
In the Research Briefing of May 27th 1) The intensity of an LSD experience as predicted by your genes 2) A brain on psilocybin becomes less segregated 3) Bringing people from different worlds together through ayahuasca
In the Research Briefing of May 19th 1) The most complete picture we have of our brains on LSD 2) Psychedelics may help us explore consciousness, we should also be aware of what we can’t explain
In the Research Briefing of May 12th: 1) MAPS reports a successful trial of MDMA-assisted therapy for PTSD 2) Moving past mysticism in psychedelic research 3) Psychedelic users appear to be more resilient in the face of Covid
Claude Weill argues that the successful integration of psychedelics and empathogenic substances can lead to long-term meaning and fulfilment.
In the Research Briefing of May 6th: 1) A new biosensor helps identify which molecules are hallucinogenic 2) Microdosing and awe, experiencing the sublime on psilocybin 3) Large meta-analysis finds esketamine lowers depression scores